v3.26.1
Revenue (Tables)
 6 Months Ended
Jun. 30, 2026
Revenue [abstract]  
Schedule of revenue by type, collaboration partner, and product under agreements.
The table below summarizes Genmab’s revenue by type and collaboration partner, and royalties by product, under Genmab’s agreements.
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue by type:
Royalties$966 $789 $1,708 $1,378 
Net product sales145 101 261 176 
Reimbursement revenue12 13 20 36 
Milestone revenue10 1 26 13 
Collaboration revenue22 21 36 37 
Total$1,155 $925 $2,051 $1,640 
Revenue by collaboration partner:
J&J$783 $656 $1,375 $1,137 
Roche31 21 57 46 
Novartis144 109 261 200 
BioNTech4 11 4 30 
Pfizer23 22 39 41 
Other**25 5 54 10 
Total*$1,010 $824 $1,790 $1,464 
Royalties by product:
DARZALEX$744 $638 $1,306 $1,088 
Kesimpta143 108 259 198 
TEPEZZA31 20 57 45 
Other**48 23 86 47 
Total$966 $789 $1,708 $1,378 
*Excludes Genmab’s Net product sales
**Other consist of royalties from net sales of RYBREVANT, TECVAYLI, TALVEY, TEPKINLY and BIZENGRI as well as milestones from collaboration partners